KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer

Cancer Letters

Volumn 332, Issue 1, 2013, Pages 74-82

  Hong, Sang Won ^a,b   Jung, Kyung Hee ^a   Park, Byung Hee ^a   Zheng, Hong Mei ^a   Lee, Hee Seung ^a   Choi, Myung Joo ^a   Yun, Jeong In ^c   Kang, Nam Sook ^c,d   Lee, Jongkook ^c,e   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d Chungnam National University   (South Korea)

^e Kangwon National University   (South Korea)

Author keywords

Angiogenesis; Apoptosis; Gastric cancer; KRC 408

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CD34 ANTIGEN; FLUOROURACIL; KRC 408; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STOMACH CANCER; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING;

AMINOPYRIDINES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD34; APOPTOSIS; BENZOXAZOLES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TIME FACTORS; TISSUE CULTURE TECHNIQUES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; RATTUS;

EID: 84875241735     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.015     Document Type: Article

References (38)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
2. Kim H.J., Karpeh M.S. Surgical approaches and outcomes in the treatment of gastric cancer. Seminars in Radiation Oncology 2002, 12:162-169.
3. Sugano K. Gastric cancer: pathogenesis, screening, and treatment. Gastrointestinal Endoscopy Clinics of North America 2008, 18:513-522.
4. Ma W.W., Adjei A.A. Novel agents on the horizon for cancer therapy. CA: A Cancer Journal for Clinicians 2009, 59:111-137.
5. Kaji M., Yonemura Y., Harada S., Liu X., Terada I., Yamamoto H. Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Therapy 1996, 3:393-404.
6. Trusolino L., Bertotti A., Comoglio P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nature Reviews Molecular Cell Biology 2010, 11:834-848.
7. Peschard P., Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007, 26:1276-1285.
8. Organ S.L., Tong J., Taylor P., St-Germain J.R., Navab R., Moran M.F., Tsao M.S. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. Journal of Proteome Research 2011, 10:3200-3211.
9. Conrotto P., Valdembri D., Corso S., Serini G., Tamagnone L., Comoglio P.M., Bussolino F., Giordano S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005, 105:4321-4329.
10. Yi S., Tsao M.S. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000, 2:226-234.
11. Di Renzo M.F., Olivero M., Martone T., Maffe A., Maggiora P., Stefani A.D., Valente G., Giordano S., Cortesina G., Comoglio P.M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19:1547-1555.
12. Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J., Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S., Zhuang Z., Schmidt L., Zbar B., Lee J.Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Research 1999, 59:307-310.
13. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M., Zbar B. GermLine and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics 1997, 16:68-73.
14. Christensen J.G., Burrows J., Salgia R. C-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters 2005, 225:1-26.
15. Kuniyasu H., Yasui W., Kitadai Y., Yokozaki H., Ito H., Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochemical and Biophysical Research Communications 1992, 189:227-232.
16. Amemiya H., Kono K., Itakura J., Tang R.F., Takahashi A., An F.Q., Kamei S., Iizuka H., Fujii H., Matsumoto Y. C-Met expression in gastric cancer with liver metastasis. Oncology 2002, 63:286-296.
17. Nakajima M., Sawada H., Yamada Y., Watanabe A., Tatsumi M., Yamashita J., Matsuda M., Sakaguchi T., Hirao T., Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
18. Retterspitz M.F., Monig S.P., Schreckenberg S., Schneider P.M., Holscher A.H., Dienes H.P., Baldus S.E. Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Research 2010, 30:4635-4641.
19. Tang Z., Zhao M., Ji J., Yang G., Hu F., He J., Shen H., Gao Z., Zhao A., Li J., Lu Y. Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncology Reports 2004, 11:333-339.
20. Sharma N., Adjei A.A. In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Therapeutic Advances in Medical Oncology 2011, 3:S37-50.
21. Cho S.Y., Han S.Y., Ha J.D., Ryu J.W., Lee C.O., Jung H., Kang N.S., Kim H.R., Koh J.S., Lee J. Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 2011, 20:4223-4227.
22. Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R., Rusconi L., Cristiani C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:12654-12659.
23. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. Journal of Molecular Graphics and Modelling 2003, 21:289-307.
24. Zhang Y.W., Wang L.M., Jove R., Vande Woude G.F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 2002, 21:217-226.
25. Recio J.A., Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002, 21:1000-1008.
26. Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P., Giordano S., Graziani A., Panayotou G., Comoglio P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261-271.
27. Nebreda A.R., Ferby I. Regulation of the meiotic cell cycle in oocytes. Current Opinion in Cell Biology 2000, 12:666-675.
28. Smits V.A., Medema R.H. Checking out the G(2)/M transition. Biochimica et Biophysica Acta 2001, 1519:1-12.
29. Vigna E., Pacchiana G., Mazzone M., Chiriaco C., Fontani L., Basilico C., Pennacchietti S., Comoglio P.M. " Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Research 2008, 68:9176-9183.
30. Pan B.S., Chan G.K., Chenard M., Chi A., Davis L.J., Deshmukh S.V., Gibbs J.B., Gil S., Hang G., Hatch H., Jewell J.P., Kariv I., Katz J.D., Kunii K., Lu W., Lutterbach B.A., Paweletz C.P., Qu X., Reilly J.F., Szewczak A.A., Zeng Q., Kohl N.E., Dinsmore C.J. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Research 2010, 70:1524-1533.
31. Sun B., Liu R., Xiao Z.D., Zhu X. C-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS ONE 2012, 7:e30143.
32. Li Y., Zhang S., Tang Z., Chen J., Kong W. Silencing of c-Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells. Tumour Biology 2011, 32:1217-1224.
33. Que W., Chen J., Chuang M., Jiang D. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS 2012, 120:195-203.
34. Chen H.H., Su W.C., Lin P.W., Guo H.R., Lee W.Y. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Research and Treatment 2007, 103:167-175.
35. Garcia S., Dales J.P., Charafe-Jauffret E., Carpentier-Meunier S., Andrac-Meyer L., Jacquemier J., Andonian C., Lavaut M.N., Allasia C., Bonnier P., Charpin C. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. International Journal of Oncology 2007, 31:49-58.
36. Shojaei F., Lee J.H., Simmons B.H., Wong A., Esparza C.O., PlumLee P.A., Feng J., Stewart A.E., Hu-Lowe D.D., Christensen J.G. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Research 2010, 70:10090-10100.
37. Ponzo M.G., Lesurf R., Petkiewicz S., O'Malley F.P., Pinnaduwage D., Andrulis I.L., Bull S.B., Chughtai N., Zuo D., Souleimanova M., Germain D., Omeroglu A., Cardiff R.D., Hallett M., Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12903-12908.
38. Ding S., Merkulova-Rainon T., Han Z.C., Tobelem G. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003, 101:4816-4822.